triumph-1 trial retatrutide results: Retatrutide, the triple agonist. Significant weight loss ( 28.3% average loss at 80 weeks). It has potential to transform obesity treatment with results comparable to… Lilly's triple agonist, retatrutide, delivered

Medicare coverage limitations significantly impact usage patterns, with only 1% of adults over 65 using GLP-1 medications for weight loss compared to higher rates in younger populations ^19

These improvements may also impact the broader medical insurance sector, potentially leading to both reduced premiums and reduced claims burdens

Tirzepatide adds GIP receptor activation, making it a dual agonist

They should also ask about protein intake, resistance training, hydration, constipation prevention, blood sugar monitoring, liver and kidney markers, and long-term maintenance after weight loss

Programs like TrimRX offer valuable support, including personalized consultations, custom dosing plans for GLP-1 medications (like Semaglutide, Tirzepatide, Mounjaro, Zepbound, Wegovy, and Ozempic), and unlimited check-ins to adjust your strategy as needed

For research laboratory professionals only